New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

NUBEQA (darolutamide) tablets, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

NUBEQA is a prescription medicine. NUBEQA used for prostate cancer treatment.
INDICATIONS AND USAGE
NUBEQA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
DOSAGE FORMS & STRENGTHS
Tablets: 300 mg
Manufactured By: Bayer
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “NUBEQA (darolutamide) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category
NUBEQA (darolutamide) tablets, for oral use.
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

Darolutamide was patented in 2011, and was approved for medical use in July 2019. It was approved for medical use in the European Union in March 2020,and in Australia in July 2020.

Related Products

Related products